Cellivery Therapeutics, Inc.
KOSDAQTotal Valuation
Cellivery Therapeutics, Inc. carries a market capitalization of 248.38B, placing it among publicly traded companies globally. Its enterprise value stands at -2.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 248.38B |
| Enterprise Value | -2.17B |
Share Statistics
Cellivery Therapeutics, Inc. currently has 37.14M shares outstanding.
| Shares Outstanding | 37.14M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 4.59 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Cellivery Therapeutics, Inc. maintains a current ratio of 0.07, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.07 |
| Quick Ratio | N/A |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -4.51 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -22.94 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 447,370.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Cellivery Therapeutics, Inc.'s stock has declined approximately -74.69697% over the past 52 weeks. The 50-day moving average sits at 11,492.60, while the 200-day moving average is 12,832.53.
| Beta (5Y) | N/A |
| 52-Week Price Change | -74.69697% |
| 50-Day Moving Average | 11,492.60 |
| 200-Day Moving Average | 12,832.53 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Cellivery Therapeutics, Inc. generated 24.54B in revenue and converted that into -6.13B in net income, yielding earnings per share of -578.72. EBITDA reached -14.14B, while operating income came in at -14.14B.
| Revenue | 24.54B |
| Gross Profit | 109.13M |
| Operating Income | -14.14B |
| Pretax Income | -21.89B |
| Net Income | -6.13B |
| EBITDA | -14.14B |
| EBIT | -14.14B |
| Earnings Per Share (EPS) | -578.72 |
Balance Sheet
| Cash & Cash Equivalents | N/A |
| Total Debt | N/A |
| Net Debt | N/A |
| Equity (Book Value) | N/A |
| Book Value Per Share | N/A |
| Working Capital | -40.03B |
Cash Flow
Cellivery Therapeutics, Inc. produced 1.47B in operating cash flow over the past twelve months. After subtracting 8.18M in capital expenditures, free cash flow totaled 1.48B - equivalent to 39.19 per share.
| Operating Cash Flow | 1.47B |
| Capital Expenditures | 8.18M |
| Free Cash Flow | 1.48B |
| FCF Per Share | 39.19 |
Margins
Cellivery Therapeutics, Inc. operates with a gross margin of 0.44, reflecting its pricing power and cost economics. The operating margin of -57.64 and net profit margin of -24.97 provide insight into operational efficiency.
| Gross Margin | 0.44 |
| Operating Margin | -57.64 |
| Pretax Margin | -89.21 |
| Profit Margin | -24.97 |
| EBITDA Margin | -57.64 |
Stock Splits
Cellivery Therapeutics, Inc.'s most recent stock split took place on July 25, 2022 with a 1:2 split ratio.
| Last Split Date | 7/25/2022 |
| Split Ratio | 1:2 |
Scores
Cellivery Therapeutics, Inc. posts an Altman Z-Score of -3.38, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.38 |